Fairmount Funds Management LLC
CIK 1802528 · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$329.46M
Companies
8
Total Filings
28
Lifetime Open-Market Net
-$1.33B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYRE | Director | 0 | $99.96 | $0 | -$1.60B | 3 | 2026-06-23 |
| JBIO | Director | — | $19.70 | — | $0 | 1 | 2026-06-11 |
| VRDN | Director | 5,090,928 | $19.51 | $99.32M | $279.99M | 6 | 2026-05-13 |
| COGT | Director | 5,503,418 | $40.67 | $223.82M | -$82.90M | 7 | 2026-01-22 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 2,747,866 | $15.70 | $43.14M | $72.95M | 1 | 2025-12-08 |
| APGE | Director | — | $134.17 | — | $0 | 1 | 2025-06-20 |
| DNTH | Director | 62,146 | $101.61 | $6.31M | $0 | 2 | 2024-04-01 |
| Cogent Biosciences, Inc. (UMRX) Delisted | 10%+ Owner | 1,147,406 | — | — | $0 | 2 | 2020-07-13 |
Recent Filings · Page 2 of 3
28 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-27 | VRDN | Buy (P) | +1,363,635 | $30.00M | EDGAR |
| 2025-07-14 | COGT | Buy (P) | +2,777,777 | $25.00M | EDGAR |
| 2025-06-20 | APGE | Grant (A) | — | $0 | EDGAR |
| 2025-06-11 | VRDN | Exer (M) | +42,300 | $499.1K | EDGAR |
| 2024-09-17 | VRDN | Buy (P) | +4,800,000 | $90.00M | EDGAR |
| 2024-06-12 | COGT | Exer (M) | +1,500,000 | $0 | EDGAR |
| 2024-05-16 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2024-04-01 | DNTH | Other (J) | — | $0 | EDGAR |
| 2024-04-01 | COGT | Other (J) | — | $0 | EDGAR |
| 2024-02-16 | COGT | Grant (A) | +1,166,666 | $8.75M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.